The objective of this study was to develop an adenoviral vector system that would generate a pattern of expression of exogenous therapeutic genes appropriate for the treatment of ovarian cancer. For this purpose, we have generated a replication-deficient recombinant adenoviral vector, AdLPLacZ, which contains the human L-plastin (LP) promoter (LP-P) driving the Escherichia coli LacZ gene. LP is constitutively expressed at high levels in malignant epithelial cells but is not expressed in normal tissues, except at low levels in mature hematopoietic cells. Because adenoviral vectors infect early hematopoietic multilineage precursor cells only poorly or not at all, this vector would be of use in the peritoneal cavity and in vitro for marrow purging. We first analyzed the expression of the LacZ reporter gene in ovarian and breast cancer cell lines, normal fibroblasts, and leukemia cell lines using the adenoviral vector in which the LacZ gene is governed by the LP-P promoter (AdLPLacZ) or in which the LacZ gene is governed by the cytomegalovirus (CMV) promoter (AdCMVLacZ). We found equivalent and high levels of expression of ␤-galactosidase (␤-gal) by AdLPLacZ and AdCMVLacZ vectors in the breast or ovarian cancer cell lines as well as in a fibrosarcoma cell line, indicating that the adenoviral vectors infected these cells and expressed their transgenes equally with the LP and CMV promoters. Expression of the LacZ gene with the CMV vector but not with the LP-P vector was observed in experiments with normal fibroblasts, indicating that the vectors infected the cells, but that the LP-P was not active within them. In hematopoietic cells such as U937 cells, no measurable ␤-gal activity was detected in cells infected either by AdLPLacZ or by AdCMVLacZ, indicating that the adenoviral vectors were not infecting the cells. Although ␤-gal activity was observed in fresh ascitic ovarian cancer cells after infection with adenoviral vectors containing CMV or the LP promoters, ␤-gal activity was detected in a portion of a biopsy of normal peritoneum when the tissues were exposed to the AdCMVLacZ vector, but not when tissues were exposed to the AdLPLacZ vector. These results suggest that the transcription of therapeutic genes in cells infected by the AdLP vectors would be restricted to LP expression-positive ovarian carcinoma cells but would not be seen in the normal mesothelial cells of the peritoneal cavity. This possibility implies that adenoviral vectors carrying therapeutic genes driven by the LP-P would be of use for the intracavitary treatment ovarian cancer.
G ene therapy represents a potentially novel approach to cancer treatment, in which the transfer of genetic material into a specific cell type alters the phenotype of the target cells [1] [2] [3] in a way that improves the outcome of therapy. Adenoviral vectors have become the most widely used vector for the delivery of prodrug activation transcription units in the field of cancer gene therapy. 4 -8 However, one of the limitations of this vector system for cancer gene therapy may be its broad cellular host range, which results in toxicity to both the tumor cells and the surrounding normal cells. One way to circumvent this limitation would be through the use of a tumor-or tissue-specific promoter for the therapeutic gene carried by the vector, which is active in the target tumor cells but not in the normal cells. Comparative examination studies of protein synthesis in normal and neoplastic human fibroblasts that were conducted in the laboratory of J.L. 9 -12 led to the discovery of L-plastin (LP), a gene that codes for an actinbinding protein, which is expressed at high levels in human epithelial cancer cells.
In their review of solid tumors, LP was found to be a marker expressed at high levels in the majority of human cancer cells of nonhematopoietic origin. 9 -12 A survey of simian virus 40-transformed human fibroblasts and human sarcoma cell lines as well as human carcinoma cell lines has demonstrated that the LP gene was transcriptionally active, although at widely varying degrees, in nearly all of the human cancer cells tested. 9 -12 In particular, high levels of LP synthesis are found in tumors derived from female reproductive organs. 12 In addition, the LP gene seems to be transcriptionally regulated through the 5.1 kilobases (kb) of the 5Ј-regulatory region. [11] [12] Because the adenoviral vector has a wide host range in epithelial cells, we proposed using the LP promoter (LP-P) in an adenoviral vector to restrict the expression of the adenoviral vector therapeutic gene to the LP-positive carcinoma cells, so as to avoid expression in normal cells. In the present study, we generated a replication-deficient adenoviral vector carrying the LacZ gene in a transcriptional unit governed by a truncated LP-P (a 2.4-kb subset of the 5Ј-promoter region of the LP gene) to accommodate both the LP-P and therapeutic genes. We subsequently studied the use of this LP LacZ adenoviral vector in various human cell lines and patient samples to determine the pattern of its transgene expression in neoplastic and normal cells.
MATERIALS AND METHODS

Generation of AdLPLacZ
We obtained a replication-incompetent adenoviral type 5-based vector from which the E1 and E3 genes were deleted (provided by the laboratory of R.G.C., The New York Hospital, Cornell Medical Center). [3] [4] [5] The AdLPLacZ vector is a modification of the vector obtained from the this laboratory, in which the human LP-P and the Escherichia coli LacZ gene that codes for ␤-galactosidase (␤-gal) have been introduced by the Deisseroth laboratory into the E1 region. The first step in the generation of AdLPLacZ was to construct an E1 shuttle vector, pLPLacZ, which contains the expression cassette of the LacZ gene under the control of the human LP-P. This was accomplished as follows: we first isolated a ScaI 2.4-kb fragment (i.e., Ϫ2265 to ϩ118 base pairs (bp)) of the human LP-P from the pHLPr-␤-gal-Neo plasmid, which was obtained from J.L. (Palo Alto Medical Research Institute), 9 -12 as shown in Figure 1 . At the beginning of the construction, the vector was identical with that outlined by Hirschowitz et al. 5 We then ligated the ScaI 2.4-kb fragment to the HincII site of pBluescript II SK Ϫ (Stratagene, La Jolla, Calif), to produce pLPSK (see Fig 1) . The SpeI/XhoI-digested 2.4-kb fragment of pLPSK was then ligated to the SpeI/XhoI-digested pCMV␤-P (obtained from R.G.C.) [3] [4] [5] after removing the cytomegalovirus (CMV) enhancer/promoter to obtain pLPLacZ (see Fig 1) . The adenovirus vector AdLPLacZ was produced by homologous recombination using standard techniques. 3 For homologous recombination to occur, pBHG10 (Microbix Biosystems, Ontario, Canada) and pLPLacZ were cotransfected into 293 cells by the calcium phosphate coprecipitation method. Individual plaques were screened, and the identity of each as AdLPLacZ was verified (see Fig 2) by amplifying part of the sequences of the LacZ gene and Ad5 by polymerase chain reaction (PCR). The sequences of the primers used for the screen were as follows: the forward primer of Ad5, 5Ј-TCGTTTCTCAG-CAGCTGTTG-3Ј, and the reverse primer of Ad5, 5Ј-CATCT-GAACTCAAAGCGTGG-3Ј, were located at 11 and 13.4 map units of the Ad5 genome, respectively, which generated a 860-bp PCR product as published previously. 13 The primer set for the LacZ gene was designed according to the sequence information for the pCMV␤-gal plasmid provided by Clontech (Palo Alto, Calif). The forward primer of LacZ gene included from Ϫ2072 to Ϫ2092 bp (5Ј-CCTGCTGATGAAGCA-GAAC-3Ј); the reverse primer was from Ϫ2340 to Ϫ2358 bp (5Ј-CGATTAGTGCTGCGCGACA-3Ј), which generated a 287-bp PCR product. The results of the PCR assays (see Fig 2) documented the introduction of the LacZ transcription unit into the adenoviral vector.
AdLPLacZ and control virus (AdCMVLacZ), which contained a CMV promoter driving the LacZ gene (obtained from the laboratory of R.G.C.), were propagated in 293 cells and recovered 36 hours after infection by five cycles of freezing/ thawing of the infected cells. All viral preparations were purified by CsCl density centrifugation, dialyzed, and stored in dialysis buffer (10 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.4) and 1 mM MgCl 2 ) at Ϫ70°C before use. Titers of the viral stocks were determined by plaque assay using 293 cells by standard methods. 14 
Cell culture
Cells were maintained in Iscove's modified essential medium (Biofluids, Rockville, Md) supplemented with 10% fetal bovine sera (FBS) and 2 mM glutamine (in the case of 293 cell line); in Dulbecco's modified Eagles' medium/F12 (Life Tech- 
Preparation of patient samples
Samples of ovarian cancer or normal peritoneal surface tissue were obtained by P.E.S. as incidental specimens during diagnostic and therapeutically indicated surgical procedures for the treatment of ovarian cancer. The procurement of these samples was performed as part of protocols approved by the Yale Human Investigations Committee. The tissue samples were minced with scissors, treated with disaggregation medium and collagenase, and rinsed; viable cell counts were determined by trypan blue exclusion. Cells were then immediately exposed to the vector for a 24-hour period and subsequently stained for LacZ gene activity.
Infection of cells and detection of ␤-gal activity
For infection and the detection of ␤-gal activity by staining, cells were exposed to complete tissue culture medium supplemented at 10% by volume with AdLPLacZ crude viral lysate of an overnight culture. After 24 hours, cells were fixed at room temperature for 10 minutes with a solution of 2% formaldehyde and 0.2% glutaraldehyde, washed three times with phosphate-buffered saline, and exposed overnight to 5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) (1 mg/mL) in phosphate-buffered saline containing 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM MgSO 4 at 37°C. 15 For flow cytometric analysis and sorting (FACS) of cells for ␤-gal activity, cells (1 ϫ 10 5 cells/well in a 24-well plate) were infected with AdLPLacZ or AdCMVLacZ at a multiplicity of infection of 25 or 50 in medium containing 2% FBS for 90 minutes. At 24 or 48 hours after the initial infection, cells were subjected to FACS-gal analysis as described by Roederer et al. 15 Briefly, after harvesting by centrifugation (HL-60 and U937) or by trypsinization, cells were resuspended with 50 L of staining medium (RPMI 1640 supplemented with 4% FBS and 10 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, pH 7.4) containing chloroquine and incubated for 20 minutes at 37°C. Cells were then exposed to 50 L of 2 mM of fluorescein di-␤-Dgalactopyranoside for 60 seconds, following which 1 mL of ice-cold Quench solution (staining solution with propidium iodide) was added; subsequently, cells were further incubated on ice for 1 hour. After adding phenylethyl ␤-D-thiogalactopyranoside, cells were subjected to FACS analysis.
RESULTS
Generation of AdLPLacZ
We have generated a recombinant adenoviral vector, AdLPLacZ, in which the E. coli LacZ reporter gene is placed downstream of a 2.4-kb DNA sequence (Ϫ2263 to ϩ118 bp with respect to the transcription start site) that was taken from the human LP 5Ј transcriptional regulatory region (Fig 1) . The E3 region and most of the E1 region were removed from this vector. 4 The expression cassette containing the LP-P and the LacZ gene replaces the E1 region of the adenovirus strain 5. Lin et al 11 have indicated that activation of the LP gene in tumorigenesis is governed by cis-acting elements present in 5.1 kb of DNA located in the transcriptional regulatory region immediately 5Ј to the LP gene. However, we incorporated a 2.4-kb DNA sequence of the LP gene (Ϫ2263/ϩ118) in this study, largely attributable to the limited capacity of the adenoviral vector, pBHG10, in which a maximum of 7.5 kb of exogenous sequence can be inserted. PCR analysis of DNA isolated from plaquepurified clones of this vector (see Fig 2) documented the successful introduction of ␤-gal into these vectors. We have tested this AdLPLacZ vector in 293 cells by a staining method to determine whether this vector could produce functional ␤-gal enzyme. Intense blue staining was observed in 293 cells that have been infected with the AdLPLacZ crude viral lysate (data not shown).
Testing of AdLPLacZ in normal and neoplastic cells
To test the ability of the 2.4 kb of LP-P to direct the expression of the LacZ transgene in a tumor cell-specific manner, we infected various human cell lines with the AdLPLacZ crude viral lysate and monitored ␤-gal activ- ity by a chrometric staining with X-Gal as described in Materials and Methods. The results of this experiment are shown in Table 1 . Intensely staining blue color reactions catalyzed by the LP-LacZ adenoviral vector were produced in all of the human ovarian carcinoma cell lines tested, such as PA-1, OVCAR-3, and SKOV-3, as well as in human mammary carcinoma cell lines such as MCF-7, BT-20, MDA-MB-436, and MDA-MB-468. However, no such staining was detected in normal human skin fibroblast cell lines such as CCD-862SK and CCD-944SK, even at 3 days after initiation of the staining reaction (see Table 1 ). A human fibrosarcoma cell line, HT-1080, which expresses a high level of endogenous LP, 12 developed a dark-blue staining upon infection with this viral vector, whereas the cell line WI-26-VA4, which is not known to express LP from its endogenous gene, 12 exhibited no staining by this method. Because LP is constitutively expressed in normal mature hemopoietic cell lines, we assumed that the human leukemia cell lines U937 and HL-60 might express abundant LP. However, only a small percentage of cells exhibited a blue color upon exposure to AdLPLacZ (see Fig 3 and Tables 1 and 2 ). This low level of LacZ reactivity may be attributable to the low infectivity of early hematopoietic cells for the adenoviral vector (see below).
To measure the transduction efficiencies of the AdLP vector and the relative strength of LP-P in cell lines, we performed FACS-gal analysis of the adenoviral vectorinfected cells following exposure to the AdLPLacZ or AdCMVLacZ vectors at a multiplicity of infection (ratio of infectious viral particles to nucleated cells) of 50. At 24 -48 hours postinfection, cells were subjected to FACS-gal analysis. In Figure 3 , we present the representative results of FACS analysis of ␤-gal staining of the infected cells.
Less than 1% of the CCD-862SK and CCD-944SK normal human skin fibroblast cell lines expressed ␤-gal upon infection with AdLPLacZ, in which the LP-P was driving the LacZ gene; however, Ն25% of the cells are infectable by the adenoviral vector, as suggested by the blue color, which develops when the same cells are infected with the control vector, AdCMVLacZ, in which the CMV promoter is driving the LacZ gene. These results indicated that the absence of LacZ expression in normal skin fibroblasts infected with the LP-␤-gal adenoviral vector did not result from the low infection efficiency of AdLPLacZ in normal fibroblasts, but rather from a low transcriptional activity of the LP-P in fibroblast cell lines.
In contrast, in a cell line known to express high levels of LP (i.e., HT-1080), nearly 90% of the cells were positive for infection by the AdLPLacZ vector and for expression of the LacZ gene, as measured by positivity in the ␤-gal staining assay. Infecting SKOV-3, a human ovarian carcinoma cell line, with the AdLPLacZ and AdCMVLacZ vectors generated 70 -100% and 45% positivity of cells in the ␤-gal assay, respectively. A high percentage of ␤-gal-expressing cells was observed in MDA-MB-468 cells (a human breast carcinoma cell line) following exposure to either AdLPLacZ or AdCMVLacZ. These results suggest that the LP-P is almost as active as the CMV promoter in ovarian and breast cancer cell lines.
In contrast, only ϳ5% of the U937 human leukemia cells were positive in the ␤-gal assay when these cells were exposed to either the AdLPLacZ or the AdCMVLacZ vector, confirming the fact that adenoviral vector infects early hematopoietic cells very inefficiently or not at all. 16 -18 These results, which were obtained from six independent experiments, are summarized in Table 2 . The relative activities of the LP and CMV transcriptional promoters in infected cell lines, when measured by the percentage of ␤-gal-positive cells, are also documented by these data. In summary, the AdLP vector system could direct the expression of a heterologous gene in a neoplastic cell-dependent manner. These data suggest that the level of expression would be dependent upon the endogenous level of LP expression.
Testing of AdLPLacZ in normal peritoneum and ascitic ovarian cancer cells from patients To determine the susceptibility to infection by adenoviral vectors and the level of expression of transgenes driven by the LP-P in ovarian cancer cells and normal mesothelial peritoneal lining cells obtained from patients, we incubated ascitic ovarian cancer cells and a portion of a biopsy of the normal mesothelial cells of the peritoneum with either the AdLPLacZ or the AdCMVLacZ vectors overnight. At 2 days after infection, ␤-gal expression was determined by X-Gal staining. As shown in Figure 4 , LacZ expression was visible in the ascitic ovarian cancer cells that had been infected with AdLPLacZ (Fig 4, A and C) as well as with AdCMVLacZ (Fig 4, B and D) . In the portion of the peritoneal biopsy that contained normal mesothelial cells, however, the cells did not produce any blue staining upon infection with the vector in which the LacZ gene is under the control of the LP-P ( Fig 4E) ; cells that had been infected with a vector in which LacZ gene is driven by the CMV promoter expressed the ␤-gal in a dose-dependent manner (Fig 4F) .
In summary, an adenovirus vector with a CMV promoter infected and expressed the LacZ gene in ascitic ovarian cancer cells as well as in normal peritoneal mesothelial cells. However, an adenoviral vector with the LP-P directing the LacZ gene was expressed in ovarian cancer cells but not in the normal mesothelial cells obtained from a single patient at the time of a therapeutically indicated surgical procedure. These studies indicated that the ascitic ovarian cancer cells and normal mesothelial cells were both infectable by the adenoviral vectors, because they both expressed the LacZ gene driven by the CMV promoter in an adenoviral vector. In contrast, the LP-P-driven LacZ adenoviral transcription unit was expressed in the ovarian cancer cells but not in the normal mesothelial cells.
DISCUSSION
Usually the extent of expression of therapeutic transgenes in cells infected by the adenoviral vectors carrying those genes in a transcription unit driven by the CMV Figure 4 . X-Gal staining studies of normal mesothelial cells and malignant ascites from an ovarian cancer patient. Fresh samples from patients were exposed to 0.5 mL of medium containing 150 million plaque-forming units of the adenoviral vector (except for E and F, in which 50 million plaque-forming units were used) for 90 minutes, washed, and incubated in the absence of the vector for another 24 hours; next, samples were exposed to the conditions of the X-Gal staining. Ascitic ovarian cancer cells were infected with either the AdLPLacZ (A and C) or the AdCMVLacZ (B and D) vectors. Biopsy cells from the mesothelium of patients undergoing surgical procedures were exposed to either the AdLPLacZ (E) or AdCMVLacZ (F) vectors.
promoter is determined largely by infection efficiency. The sensitivity of a cell to infection by the adenoviral vector depends not only upon the number of receptors on the cell surface for the fibrillar protein, which mediates binding, but also upon the presence of the ␣V␤3 and ␣V␤5 integrins that bind to the adenovirus penton base proteins, thereby mediating the uptake of the adenovirus at the cell membrane level and its release from postuptake endosomes. 19, 20 As an example, epithelial cells are readily infectable by the adenoviral vector, but early hematopoietic cells, because they do not contain the requisite integrin receptors, are not readily infectable without an induction of differentiation of these cells, which increases the levels of the necessary integrins on the cell surface (see Refs. 19 -21). However, in this study, we have generated an adenoviral vector system that contains 2.4 kb of LP-P regulating the expression of the LacZ reporter gene in neoplastic cells. In cells exposed to this vector, the expression of the transgene is governed not only by the infectability of cells by the vector but also by the activity of the LP-P in the infected cells. We have demonstrated in vitro that the 2.4 kb of LP-P nearest the transcription initiation site of the gene could direct heterologous gene expression preferentially in neoplastic, but not in normal, mesothelial cells. In addition, we have shown that the LP-P activity has a strength of transcriptional activity in neoplastic epithelial cells that is comparable with that seen with the CMV promoter. Thus, the AdLP vector carrying a prodrug activation chemotherapy sensitization transcription unit may have significant utility in the chemosensitization of the ovarian cancer cells present as implants on the peritoneal surface or as ascites to intraperitoneal chemotherapy, because the LP-P in the studies presented in this paper was very active in ovarian cancer cell lines and in fresh ascitic ovarian cancer cells but was not active in cell lines of mesodermal origin or in normal peritoneal mesothelial cells.
